Endothelin antagonists and resistant hypertension in chronic kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 19, Issue 5, 2010, Pages 432-436

  Moore, Rebecca ^a   Linas, Stuart ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

chronic kidney disease; endothelin receptor antagonism; resistant hypertension; sodium retention

Indexed keywords

ATRASENTAN; DARUSENTAN; ENDOTHELIN; ENDOTHELIN A RECEPTOR ANTAGONIST;

BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; DRUG INDUCED HEADACHE; FLUSHING; HUMAN; HYPERTENSION; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RHINITIS; SIDE EFFECT; SYNCOPE;

CHRONIC DISEASE; DRUG RESISTANCE; ENDOTHELINS; HUMANS; HYPERTENSION; KIDNEY DISEASES; RECEPTORS, ENDOTHELIN;

EID: 77955923800     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32833a7a25     Document Type: Review

References (33)

1. Whitworth JA, WHO, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21:1983-1992.
2. Cutler JA, Sorlie PD, Wolz M, et al. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension 2008; 52:818-827.
3. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
4. De Wardener HE, He FJ, MacGregor GA. Plasma sodium and hypertension. Kidney Int 2004; 66:2454-2466.
5. Schmidlin O, Sebastian AF, Morris RC. What initiates the pressor effect of salt in salt-sensitive humans: observations in normotensive blacks. Hypertension 2007; 49:1032-1039.
6. Buckalew VM, Berg RL, Wang SR, et al. Prevalence of hypertension in 1795 subjects with chronic kidney disease: the modification of diet in renal disease study baseline cohort. Modification of Diet in Renal Disease Study Group. Am J Kidney Dis 1996; 28:811-821.
7. De Nicola L, Minutolo R, Zamboli P, et al. Italian audit on therapy of hypertension in chronic kidney disease: the TABLE-CKD study. Semin Nephrol 2005; 25:425-430.
8. Kohan DE. Endothelins in the normal and diseased kidney. Am J Kidney Dis 1997; 29:2-26.
9. Kohan DE. Endothelin, hypertension and chronic kidney disease: new insights. Curr Opin Nephrol Hypertens 2010; 19:134-139.
10. Verhaar MC, Strachan FE, Newby DE, et al. Endothelin-a receptor antagonist-mediated vasodilation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998; 97:752-756.
11. Hosada K, Nakao K, Tamura N, et al. Organization, structure, chromosomal assignment, and expression of the gene endcoding the human endothelin-A receptor. J Biol Chem 1992; 267:18797-18804.
12. Chow LH, Subramanian S, Nuovo GJ, et al. Endothelin receptor mRNA expression in renal medulla identified by in situ RT-PCR. Am J Physiol 1995; 269:F449-F457.
13. Nadler SP, Zimpelmann JA, Hebert RL. Endothelin inhibits vasopressin-stimulated water permeability in rat terminal inner medullary collecting duct. J Clin Invest 1992; 90:1458-1466.
14. Tomita K, Nonguchi H, Terade Y, et al. Effects of ET-1 on water and chloride transport in cortical collecting ducts of the rat. Am J Physiol 1993; 264:F690-F696.
15. Gallego MS, Ling BN. Regulation of amiloride-sensitive Na+ channels by endothelin-1 in distal nephron cells. Am J Physiol 1996; 271:F451-F460.
16. BugavV, PochynukO,MironovaE, etal. Regulation of epithelial Na+ channel by endothelin-1 in rat collecting duct. Am J Physiol 2008; 295:F1063-F1070.
17. Schneider MP, Ge Y, Pollock DM, etal. Collecting duct-derived endothelin regulates arterial pressure and Na excretion via nitric oxide. Hypertension 2008; 51:1605-1610.
18. Gomez-Garre D, Ruiz-Ortega M, Ortego M, et al. Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Hypertension 1996; 27:885-892.
19. Gutierrez S, Palacios I, Egido J, et al. Endothelin-1 induces loss of proteoglycans and enhances fibronectin and collagen production in cultured rabbit synovial cells. Eur J Pharmacol 1996; 302:191-197.
20. Chang JM, Chiu YW, Tsai JC, et al. Effects of endothelin-1 on thymidine uptake and fibronectin production of diabetic glomeruli. Nephrology 2007; 12:62-66.
21. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006; 69:2131-2147.
22. Rebibou JM, He CJ, Delarue F, etal. Functional endothelin 1 receptors on human glomerular podocytes and mesangial cells. Nephrol Dial Transplant 1992; 7:288-292.
23. Ortmann J, Amann K, Brandes RP, et al. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension 2004; 44:974-981.
24. Collino F, Bussolati B, Gerbaudo E, et al. Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am J Physiol Renal Physiol 2008; 294:F1185-F1194.
25. Barton M. Reversal of proteinuric renal disease and the emerging role of endothelin. Nat Clin Pract Nephrol 2008; 4:490-501.
26. Nakov R, Pfarr E, Eberle S, et al. Darusentan: an effective endothelin: a receptor antagonist for treatment of hypertension. Am J Hypertens 2002; 15:583-589.
27. Raichlin E, Prasad A, Mathew V, et al. Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension 2008; 52:522-528.
28. Weber MA, Black H, Bakris G, et al. A selective endothelin-receptor antago-nist to reduce blood pressure in patients with treatment-resistant hyperten sion: a randomized, double-blind, placebo-controlled trial. Lancet 2009; 374:1423-1431.
29. Cottone S, Mule G, Guarneri M, etal. Endothelin-1 and F2-isoprostane relate to and predict renal dysfunction in hypertensive patients. Nephrol Dial Transplant 2009; 24:497-503.
30. ZanattaCM, Gerchman F, Burttet L, etal. Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008; 80:299-304.
31. Wenzel RR, Littke T, Kuranoff S, et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009; 20:655-664.
32. Dhaun N, MacIntyre IM, Melville V, etal. Blood pressure-independent reduc-tion in proteinuria and arterial stiffness after acute endothelin: a receptor antagonism in chronic kidney disease. Hypertension 2009; 54:113-119.
33. Battistini B, Berthiaume N, Kelland NF, etal. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel "-sentan" class of drug. Exp Biol Med 2006; 231:653-695.